![]() |
![]() |
Legal status
Patent not validated
(51) | INT.CL. | C07D 205/04 | |
A61K 31/397 | |||
A61P 29/00 | |||
A61P 31/06 | |||
A61P 31/08 | |||
A61P 21/00 |
(11) | Number of the document | 2379499 |
(13) | Kind of document | T |
(96) | European patent application number | 09793424.4 |
Date of filing the European patent application | 2009-12-17 | |
(97) | Date of publication of the European application | 2011-10-26 |
(45) | Date of publication and mention of the grant of the patent | 2014-04-09 |
(46) | Date of publication of the claims translation |
(86) | Number | PCT/US2009/068352 |
Date | 2009-12-17 |
(87) | Number | WO 2010/080455 |
Date | 2010-07-15 |
(30) | Number | Date | Country code |
203051 P | 2008-12-18 | US |
(72) |
DE LA CRUZ, Marilyn, US
KARPINSKI, Piotr, H., US
LIU, Yugang, US
|
(73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
(54) | Hydrochloride salt of 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl)-2-ethyl-benzyl)-azetidine-3-carboxylic acid |
Hydrochloride salt of 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl)-2-ethyl-benzyl)-azetidine-3-carboxylic acid |